journal article·2016-11-16

Budesonide-loaded solid lipid nanoparticles for pulmonary delivery: preparation, optimization, and aerodynamic behavior

Maryam Esmaeili, Mahdi Aghajani, Roghayeh Abbasalipourkabir, Amir Amani

Publisher page

Abstract

Advantages of lipid nanoparticles for pulmonary applications are possibility of deep lung deposition with prolonged release and low toxicity. This study aimed to evaluate the effects of formulation and processing parameters on particle size of prepared SLNs. Budesonide-loaded solid lipid nanoparticles (BUD-SLNs) were prepared with different values of drug content, ultrasonication amplitude, and homogenization time and the data were modeled using artificial neural networks (ANNs). Optimal conditions for fabrication of small-sized particles of 170-200 nm were found to be low drug content with high-amplitude and high-homogenization time. In vitro aerosolization performance of BUD-SLNs was then compared to that of commercial budesonide which indicated enhancement in fine particle fraction value.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advancements in Transdermal Drug Delivery · Microencapsulation and Drying Processes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (36)

Show source-provided references
1. Abbasalipurkabir R · Pharm Technol · 2011 · 35 · 74
2. 10.5772/1555110.5772/15551 ↗
3. 10.1211/jpp.61.12.000610.1211/jpp.61.12.0006 ↗
4. 10.1208/s12249-010-9486-910.1208/s12249-010-9486-9 ↗
5. 10.3109/02652048.2013.87135810.3109/02652048.2013.871358 ↗
6. 10.1002/jps.2084910.1002/jps.20849 ↗
7. Bartos C · Optimization · 2014 · 62 · 1
8. Berne BJ · 2000
9. 10.1016/j.addr.2007.04.01010.1016/j.addr.2007.04.010 ↗
10. 10.1016/j.cherd.2009.11.01210.1016/j.cherd.2009.11.012 ↗
11. 10.1080/00031305.1999.1047444510.1080/00031305.1999.10474445 ↗
12. Emami HM · Res Pharm Sci · 2014 · 10 · 17
13. 10.1016/j.molcata.2010.09.01810.1016/j.molcata.2010.09.018 ↗
14. 10.1016/j.jspi.2008.10.00210.1016/j.jspi.2008.10.002 ↗
15. Gershenson C · 2003
16. 10.1007/978-3-662-06710-910.1007/978-3-662-06710-9 ↗
17. Hu L · Pharmazie Int J Pharm Sci · 2010 · 65 · 585
19. 10.1002/ppsc.20070000510.1002/ppsc.200700005 ↗
20. 10.3109/10731199.2011.59249410.3109/10731199.2011.592494 ↗
21. 10.1089/1043034005005746810.1089/10430340050057468 ↗
22. 10.1016/j.ijpharm.2009.01.01410.1016/j.ijpharm.2009.01.014 ↗
23. 10.2147/IJN.S493710.2147/IJN.S4937 ↗
24. 10.1016/S0169-409X(01)00105-310.1016/S0169-409X(01)00105-3 ↗
25. 10.1208/s12248-009-9148-610.1208/s12248-009-9148-6 ↗
26. 10.1208/s12249-009-9290-610.1208/s12249-009-9290-6 ↗
27. Nic M · 1997
28. 10.1016/j.jconrel.2010.02.00610.1016/j.jconrel.2010.02.006 ↗
29. 10.1021/bm070392310.1021/bm0703923 ↗
30. Schick C · 2008
31. 10.1016/S0169-409X(03)00119-410.1016/S0169-409X(03)00119-4 ↗
32. Sunitha R · Int J Res Pharm Chem · 2011 · 1 · 828
33. 10.1146/annurev.matsci.29.1.29510.1146/annurev.matsci.29.1.295 ↗
34. 10.1016/j.ejpb.2013.08.01310.1016/j.ejpb.2013.08.013 ↗
35. Zhang P · J Chin Pharm Sci · 2011 · 20 · 390
36. 10.3109/21691401.2014.94464510.3109/21691401.2014.944645 ↗